Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol-Myers Acquires Hepatitis C Drug
by Lisa M. Jarvis
January 19, 2009
| A version of this story appeared in
Volume 87, Issue 3
Bristol-Myers Squibb will pay at least $105 million to ZymoGenetics for a novel type 3 interferon in Phase I studies to treat hepatitis C. The Seattle-based biotech firm could collect another $430 million in milestones related to the hepatitis C program and up to $287 million if the drug is approved to treat other diseases. The drug, PEG-interferon lambda, meddles with a receptor that is present in fewer cell types than the one the conventional hepatitis C treatment, interferon alpha, uses to mediate antiviral activity. ZymoGenetics believes its drug could therefore be a more targeted treatment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter